A Congressional report alleges that consulting firm McKinsey engaged in a “serious conflict of interest” by working for the U.S. government on issues relating to the opioid epidemic while, at the same time, advising drugmakers, including on projects meant to persuade regulators about the safety of opioid products.
The U.S. House Oversight Committee alleged in its April 13 report (pdf) that at least 22 McKinsey consultants, including senior partners, worked for both the Food and Drug Administration (FDA) and opioid manufacturers, at times simultaneously.
